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Abstract
Introduction: Microtubule associated proteins (MAPs) endogenously regulate microtubule stabilization and have
been reported as prognostic and predictive markers for taxane response. The microtubule stabilizer, MAP-tau, has
shown conflicting results. We quantitatively assessed MAP-tau expression in two independent breast cancer
cohorts to determine prognostic and predictive value of this biomarker.
Methods: MAP-tau expression was evaluated in the retrospective Yale University breast cancer cohort (n = 651)
using tissue microarrays and also in the TAX 307 cohort, a clinical trial randomized for TAC versus FAC
chemotherapy (n = 140), using conventional whole tissue sections. Expression was measured using the AQUA
method for quantitative immunofluorescence. Scores were correlated with clinicopathologic variables, survival, and
response to therapy.
Results: Assessment of the Yale cohort using Cox univariate analysis indicated an improved overall survival (OS) in
tumors with a positive correlation between high MAP-tau expression and overall survival (OS) (HR = 0.691, 95% CI =
0.489-0.974; P = 0.004). Kaplan Meier analysis showed 10-year survival for 65% of patients with high MAP-tau
expression compared to 52% with low expression (P = .006). In TAX 307, high expression was associated with
significantly longer median time to tumor progression (TTP) regardless of treatment arm (33.0 versus 23.4 months,
P = 0.010) with mean TTP of 31.2 months. Response rates did not differ by MAP-tau expression (P = 0.518) or by
treatment arm (P = 0.584).
Conclusions: Quantitative measurement of MAP-tau expression has prognostic value in both cohorts, with high
expression associated with longer TTP and OS. Differences by treatment arm or response rate in low versus high
MAP-tau groups were not observed, indicating that MAP-tau is not associated with response to taxanes and is not
a useful predictive marker for taxane-based chemotherapy.
Keywords: microtubule associated protein- tau (MAP-tau), metastatic breast cancer, taxanes, prognostic, predictive,
quantitative analysis, immunohistochemistry
Introduction
Taxanes are microtubule stabilizing agents and potent
cytotoxic compounds that have been recognized as highly
effective chemotherapeutic agents [1,2]. However, varying
degrees of benefit, with response rates ranging from 32%
to 68% in the adjuvant and metastatic settings, suggest
the critical need for a companion diagnostic to predict
which patients are most likely to benefit from taxane
therapy and which can be spared the cytotoxic effects of
such therapy [3].
Taxanes induce mitotic arrest and tumor cell apoptosis
through the hyper-stabilization of microtubules. Biomar-
kers that indicate the state of microtubule stability in the
cell could be useful for predicting taxane response. Micro-
tubule associated proteins (MAPs) are endogenous regula-
tors of microtubule stability, functioning to promote or
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subsequent cell cycle progression or mitotic arrest. These
proteins may serve as potential candidates for a compa-
nion diagnostic.
MAP-tau (Tau) is a well characterized microtubule sta-
bilizer that is responsible for the bundling, spacing, and
assembly of microtubules [4-6]. MAP-tau may compete
for taxane binding sites and/or may be involved in the
cooperative binding of taxol to microtubules [7,8]. Initial
reports evaluating MAP-tau as a predictive marker have
been conflicting. Early studies measuring MAP-tau
mRNA levels in the neoadjuvant setting found signifi-
cantly lower levels in patients with pathologic complete
response [7,9] but no correlation with pathologic com-
plete response was observed in patients from a subset of
the GEPARTRIO trial [10]. Similarly, in a subset of the
Hellenic Cooperative Oncology Group (HeCOG) trial,
MAP-tau mRNA expression status was found to be non-
predictive of benefit from paclitaxel in the adjuvant set-
ting [11]. When MAP-tau protein expression was evalu-
ated, most often using traditional immunohistochemical
methods, conflicting results were also found. Within the
adjuvant setting, in the NSABP-B 28 randomized clinical
trial, there was no prediction of benefit from paclitaxel
but high MAP-tau expression was a positive prognostic
marker for improved survival [12]. In advanced breast
cancer patients, an early study of MAP-tau expression
found no prediction of benefit from taxane therapy [13].
However, two additional studies of advanced breast can-
cer patients found high MAP-tau expression predictive
for response to paclitaxel [14,15] and a positive prognos-
tic marker for improved overall survival [15].
The goal of this study was to clarify the prognostic and
predictive value of MAP-tau. Protein expression for MAP-
tau was quantitatively assessed using two independent
cohorts. Prognostic value was evaluated using a large Yale
University retrospective cohort of untreated, primary
breast cancer patients. Predictive value for MAP-tau was
assessed using tumor tissue from TAX 307, a randomized
clinical trial that examined patient response to the taxane,
docetaxel, with docetaxel as the only variable. To date, no
studies evaluating MAP-tau as a biomarker have assessed
patient response using only taxane therapy as the rando-
mized treatment variable. The TAX 307 trial randomized
docetaxel-doxorubicin-cyclophosphamide (TAC) versus 5-
fluorouracil-doxorubicin-cyclophosphamide (FAC) as
first-line chemotherapy for metastatic breast cancer.
Patients were allowed to receive prior adjuvant endocrine
therapy (tamoxifen) and/or chemotherapy but no prior
taxanes were allowed. In this trial, inclusion of docetaxel
resulted in an improved response rate (P =0 . 0 2 )b u td i d
not improve time to tumor progression (TTP) (P =0 . 5 1 )
or overall survival (P = 0.93) compared with FAC alone
[16].
Materials and methods
Patient and cohort characteristics
Formalin-fixed paraffin-embedded primary breast cancer
tumors resected from 651 patients at Yale University/
New Haven hospital between 1962 and 1983 were
obtained from the archives of the pathology department
at Yale University (New Haven, CT, USA) and have been
previously described in detail [17] (see Table S1 in Addi-
tional file 1). Specimens and associated clinical informa-
tion were collected under informed consent under the
ethics guidelines and approval of the Yale Human Inves-
tigation Committee under protocol #8219 to DLR.
The second cohort, a prospectively collected, rando-
mized phase III clinical trial, compared TAC versus FAC
[16]. Patients were enrolled between 1 January, 1998 and
31 December, 1999, with a total of 489 patients rando-
mized to receive either FAC (75/50/500 mg/m
2)o rT A C
(500/50/500 mg/m
2) as first-line chemotherapy for meta-
static breast cancer. Prior adjuvant chemotherapy (but not
a taxane and not > 240 mg/m2 doxorubicin) was allowed.
A total of 39% of patients received prior adjuvant che-
motherapy of whom 11% had received anthracyclines pre-
viously. Patients may have also received prior adjuvant
hormonal therapy (described in more detail in Results).
Cycles were repeated every three weeks for six to eight
cycles, depending on cumulative dose of prior doxorubicin
treatment. Median patient age was 54 years with median
follow-up time of 30 months, median disease-free survival
of 27 months, and median number of cycles of TAC or
FAC equal to six.
Baseline characteristics were well balanced and major
negative prognostic factors were similar in both arms. Spe-
cimens and associated clinical information were collected
under informed consent under the ethics guidelines and
approval of the Dana Farber Human Investigation Com-
mittee and Yale Human Investigation Committee under
protocol # 0804003757 to LH. Tumor blocks were avail-
able for 140 patients from this trial and represented 28.6%
of all clinical trial participants. The TAX 307 subgroup
(TAX 307S) showed no differences in patient characteris-
tics when FAC and TAC treatment randomization groups
were compared (Table 1). In addition, no significant differ-
ences in clinical characteristics were observed between
TAX 307S and the original TAX 307 cohort indicating
TAX 307S to be a representative subset.
Tissue microarrays and whole tissue slides
Tissue microarrays (TMAs) were constructed as pre-
viously described [17]. In brief, tissue specimens were
prepared for microarray format by selecting representa-
tive breast tumor areas from 651 formalin-fixed, paraf-
fin-embedded primary tumor blocks using hematoxylin
and eosin stained whole-section slides. Breast core sam-
ples 0.6 mm in diameter were arrayed in a recipient
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Treatment group
Variable FAC
1 (n = 54) TAC
2 (n = 54) P*
Menopausal status
Premenopausal 9 (16.7) 15 (27.8) 0.119
Postmenopausal 36 (66.7) 28 (51.9)
Other 9 (16.7) 11 (20.4)
Tumor size (cm)
≤ 2 9 (16.7) 15 (27.8) 0.216
2-5 29 (53.7) 27 (50.0)
≥ 5 12 (22.2) 10 (18.5)
Other 4 (7.4) 2 (3.7)
Nodal status
Negative for node metastasis 16 (29.6) 17 (31.5) 0.874
Positive for node metastasis 29 (53.7) 33 (61.1)
Other 9 (16.7) 4 (7.4)
Histology
Infiltrating ductal carcinoma 43 (79.6) 46 (85.2) 0.800
Infiltrating lobular carcinoma 5 (9.3) 5 (9.3)
Other 6 (11.1) 3 (5.6)
Tumor grade
Well/moderately differentiated 18 (33.3) 13 (24.1) 0.148
Poorly/undifferentiated 27 (50.0) 32 (59.3)
Other 4 (7.4) 1 (1.9)
Unknown 5 (9.3) 8 (14.8)
ER status
ER negative 18 (33.3) 22 (40.7) 0.398
ER positive 27 (50.0) 23 (42.6)
Other 9 (16.7) 9 (16.7)
PR status
PR negative 19 (35.2) 22 (40.7) 0.458
PR positive 25 (46.3) 21 (38.9)
Other 10 (18.5) 11 (20.4)
Prior adjuvant chemotherapy
No therapy 29 (53.7) 26 (48.1) 0.565
Yes therapy 25 (46.3) 28 (51.9)
Prior adjuvant hormonal therapy
No therapy 31 (57.4) 40 (74.1) 0.070
Yes therapy 23 (42.6) 14 (25.9)
Prior metastatic hormonal therapy
No therapy 39 (72.2) 41 (75.9) 0.662
Yes therapy 15 (27.8) 13 (24.1)
Response to therapy
Complete response (CR) 3 (5.6) 5 (9.3) 0.5844
Partial response (PR) 25 (46.3) 23 (42.6)
Stable disease (SD) 15 (27.8) 14 (25.9)
Progressive disease (PD) 9 (16.7) 7 (13.0)
Other 2 (3.7) 5 (9.3)
*P is given for chi-square analysis. Statistically significant P values (P < 0.05) are in bold.
1FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination
2TAC, docetaxel-doxorubicin- cyclophosphamide combination
ER, estrogen receptor; PR, progesterone receptor.
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tissue, liver tissue and formalin fixed, paraffin embedded
cell lines A431, BAF3, BT474, BT549, HT29, MB 231,
MB435, MB436, MB468, MCF7, SKBR3, SW480, and
T47D. Culture conditions and cell-line TMA construc-
tion have been previously published in detail [18]. Addi-
tionally, a specialized Index Array was constructed to
confirm assay reproducibility within both Yale Univer-
sity and TAX 307S cohorts and to normalize AQUA
®
scores between different immunostaining run dates.
Finally, a non-tumor TMA containing normal breast tis-
sue was constructed from breast reduction mammoplas-
ties using 110 unique patient samples with two-fold
redundancy (n = 220). The TAX 307S cohort consisted
of 140 conventional whole tissue (WT) slides of repre-
sentative tumor tissue.
Antibodies and immunofluorescence
Yale University cohort TMAs and TAX 307S WT slides
were immunostained using MAP-tau monoclonal anti-
body, which recognizes all human MAP-tau isoforms
(1:750; mouse monoclonal, clone 2B2.100/T1029; US
Biological, Swampscott, MA, USA). This antibody has
been validated by western blot analysis and siRNA knock
down [7]. For TAX 307S, serial sections of the index
array TMA were stained alongside both cohorts to con-
firm assay reproducibility. Normal breast epithelium in
the Yale University cohort TMAs and the TAX 307S WT
slides served as internal positive controls, while omission
of the primary antibody served as the negative control for
each immunostaining event. Quantitative immunofluor-
escence staining was performed as previously described
in detail (See Additional File 2).
TMA image capture and analysis
The AQUA method of quantitative immunofluorescence
has been previously described [19]. The TMA cohorts
were captured and analyzed using V1.6 of the AQUA
®
software (HistoRx, Branford, CT, USA) on the PM2000
platform. Specific parameters related to the TMA data
collection are found in Additional File 2.
Whole tissue image capture and analysis
In contrast to TMA image acquisition and analysis, WT
sections from the TAX 307 clinical trial cohort required
a different approach for image capture and analysis.
Based on the size and contours of each resection area per
slide, an image acquisition matrix was created with fields
of view (FOV) ranging from 4 to 486 discrete images per
slide. To avoid sampling bias in tumor image selection
and to address issues of potential MAP-tau tissue hetero-
geneity, all cytokeratin-stained regions (rather than a
variable number of regions selected at random) were
collected for each tissue and quantitatively analyzed. A
total of 15,816 images were collected and assessed for
MAP-tau expression from the 140 cases received from
the TAX 307 clinical trial. Not all cases were available for
evaluation with a total of 22 cases (15.7%) missing due to
tissue loss during staining or incomplete clinical trial
data.
Statistical analysis
Average values for MAP-tau AQUA scores from the
TMA were calculated from two-fold redundant samples
and treated as independent continuous variables. The
median expression level of MAP-tau from normal breast
tissue served as the pre-defined cutpoint to differentiate
high from low MAP-tau expression in both cohorts. Chi-
square analysis was used to compare TAX 307S patient
characteristics between FAC and TAC treatment groups
to ensure intra-group comparability and to compare
TAX 307S patient characteristics with those of the origi-
nal TAX 307 clinical trial cohort. Survival curves for
both cohorts were constructed using Kaplan Meier meth-
ods and the Cox-Mantel log-rank test was used to calcu-
late the association between expression and survival.
Two survival endpoints were used in this analysis. Over-
all survival (OS) was assessed for the Yale University
cohort while TTP was evaluated for the TAX 307 clinical
trial cohort. Cox proportional hazards regression analysis
was used to determine which independent factors signifi-
cantly impacted OS. Analyses used OS in the Yale Uni-
versity cohort and progression-free survival (PFS) in the
TAX 307S cohort. To evaluate the association between
patient response and MAP-tau expression levels, chi-
square analysis was performed. Tau-by-treatment inter-
action was calculated to assess the relation between
MAP-tau expression and docetaxel efficacy. All P values
were based on two-sided testing and differences were
considered significant at P < 0.05. Statistical analysis was
performed using JMP Statistical Discovery Software, Ver-
sion 7.0.1 (SAS Institute, Inc., Cary, NC, USA) and R,
Version 2.8.0 (R Development Core Team).
Results
MAP-tau expression and distribution
In order to establish a cutpoint that could be used to dif-
ferentiate high versus low MAP-tau expression in
patients, MAP-tau was measured in normal epithelial
ducts and lobules in TMA format (n = 220). Average
MAP-tau expression scores in normal breast tissue
showed mean and median AQUA scores of 489 and 462,
respectively, with a score range of 157 to 1425. The med-
ian MAP-tau expression score in normal breast tissue
was subsequently used in all analyses to differentiate high
expressers (AQUA score ≥ 462) from low expressers
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malized to this AQUA score range using the index array
TMA.
We examined MAP-tau expression within the Yale
University cohort (n = 651), and found cytoplasmic loca-
lization similar to our observations in normal breast tis-
sue (Figure 1a). The frequency distribution of average
MAP-tau expression scores in the Yale University cohort
indicated mean and median AQUA scores of 498 and
210, respectively, with a range of 54 to 3017 (Figure 1b).
A total of 480 cases had sufficient tumor tissue for analy-
sis with 22% classified as high MAP-tau expressers com-
pared with 78% as low expressers.
Estrogen receptor (ER)-negative cases showed signifi-
cantly more frequent low MAP-tau (48.6%) compared
with ER-positive cases (29.9%) (P < 0.0001) and this
trend was mirrored for progesterone receptor (PR) status
as well (Table 2). For HER2 expression, an inverse corre-
lation between MAP-tau and human epidermal growth
factor receptor (HER) 2-positive expression was observed
with high MAP-tau present in only 2.4% of HER2-posi-
tive patients compared with 19.1% with high MAP-tau in
HER2-negative cases. This was a particularly interesting
observation as MAP-tau exists adjacent to HER2 on the
17q12 amplicon, yet rarely appears co-expressed in
HER2-positive tumors. MAP-tau expression did not cor-
relate with menopausal status, tumor size, nuclear grade,
or nodal status (Table 2).
MAP-tau prognostic value in the Yale University cohort
Patients with high MAP-tau expression (n = 94) showed
improved survival compared with those with low expres-
sion (n = 339) (68.3% vs 52.9%, respectively; log-rank, P =
0.006, Figure 2a). When stratified by ER status, MAP-tau
showed prognostic value in ER-negative but not in ER-
positive patients (Figure 2b). In the ER-negative/high
MAP-tau expressers (n = 35) we observed improved sur-
vival compared with low expressers (n = 209; 78% vs
42%; log-rank, P = 0.006). Similarly, patients stratified by
HER2 status showed improved survival for high MAP-
Tau/HER2 positive expression compared with low MAP-
tau/HER2 positive expression (log rank P = 0.007, Figure
2c), although the coexpression of MAP-tau and HER2
was a rare event. Univariate analysis showed that high
0
50
100
150
200
250
0 500 1000 1500 2000
A B
MAP-tau Expression in Yale Cohort (AQUA Score)
P
a
t
i
e
n
t
s
 
(
n
u
m
b
e
r
)
300
350
Preselected cutpoint 
based on normal breast 
tissue MAP-tau expression
462
i. ii.
iv. iii.
Figure 1 MAP-tau expression and frequency distribution in Yale University cohort with two-fold redundancy. (a) Representative case
from the Yale University cohort TMA showing cytoplasmic localization of MAP-tau within breast tumor tissue (two-fold redundancy; n = 651). (i)
Pixel binary gating demarcating epithelial tumor area from stroma in order to define the tumor compartment; (ii) immunofluorescence of MAP-
tau-Cy5 (red) expression pattern (continuous score of 789); (iii) target protein MAP-tau-Cy5 (red) colocalization with cytokeratin-Cy3, a marker for
breast epithelia (green); (iv) Localization of nuclear DAPI (blue) relative to colocalization of target protein MAP-tau-Cy5 (red) with cytokeratin-Cy3,
a marker for breast epithelia (green). Original magnification x20. (b) Yale frequency distribution of average MAP-tau expression scores in the Yale
University cohort with preselected cutpoint 462, the median MAP-tau expression score observed in normal breast tissue and used to differentiate
high expressors from low expressors.
Baquero et al. Breast Cancer Research 2011, 13:R85
http://breast-cancer-research.com/content/13/5/R85
Page 5 of 18MAP-tau expression and ER and PR positive status were
associated with significantly better OS (hazard ratio
(HR) = 0.766 and 0.675; 95% confidence interval (CI),
0.598 to 0.981 and 0.524 to.871, P = 0.0005 and P <
0.0001, respectively), while large tumor size, nodal metas-
tasis, increasing number of positive nodes, total nodes, and
nuclear grade, were associated with worse OS (Table 3). In
multivariate analysis, high MAP-tau expression was again
associated with significantly improved OS. For patients
with high MAP-tau expression, we observed a 24% reduc-
tion of risk (HR = 0.765; 95% CI, 0.598 to 0.957, P = 0.018;
Table 4). In contrast, large tumor size, nodal metastasis,
increasing total nodes, and positive HER2 status were
associated with worse OS.
MAP-tau expression pattern in TAX 307S
In the TAX 307S metastatic cohort, MAP-tau expression
was measured in each WT section using a matrix
comprised of FOVs. All FOVs were collected and AQUA
scores were generated, but each region was reviewed on a
serial H&E slide to confirm that all FOVs represented
infiltrating carcinoma. FOVs with normal breast ducts or
ductal carcinoma in situ were excluded from the analysis.
This process is illustrated in Figures 3a and 3b. Similar to
t h eY a l eU n i v e r s i t yc o h o r t ,M A P - t a ue x p r e s s i o ni nT A X
307S remained localized to the cytoplasmic compartment
within the epithelial tumor area. A total of 15,816 indivi-
dual, non-overlapping FOVs were evaluated in the TAX
307S cohort. A frequency distribution summarizing the
FOVs was generated for each case in the TAX 307S
cohort (Figure 3c). The median score from all FOVs
from each case was used to represent that case in the
final subset of 108 cases. The distribution of MAP-tau
expression in TAX307 for a single patient case is illu-
strated in Figure 3d. The median level of normal MAP-
tau expression as previously applied in the Yale
Table 2 Correlation between MAP-tau expression and clinicopathologic variables in the Yale University cohort
MAP-tau expression
Variable Low (%) (AQUA score < 462) High (%) (AQUA score > 462) P*
Menopausal status
Premenopausal 108 (22.8) 31 (6.5) 0.734
Postmenopausal 265 (55.9) 70 (14.8)
Tumor size
< 2 cm 128 (29.1) 31 (7.1) 0.535
2-5 cm 155 (35.2) 50 (11.4)
> 5 cm 59 (13.4) 17 (3.9)
Nuclear grade
Small/uniform nuclei 60 (13.4) 15 (3.4) 0.225
Intermediate nuclei 182 (40.6) 61 (13.6)
Large nuclei 107 (23.9) 23 (5.1)
Nodal status
Node positive 199 (41.8) 47 (9.9) 0.201
Node negative 175 (36.8) 55 (11.6)
ER
Negative 227 (48.6) 38 (8.1) < 0.0001
Positive 140 (29.9) 62 (13.3)
PR
Negative 240 (52.4) 31 (6.8) < 0.0001
Positive 120 (26.2) 67 (14.6)
HER2
Negative 283 (61.3) 88 (19.1) 0.010
Positive 80 (17.3) 11 (2.4)
*P is given for chi-square analysis. Statistically significant P values (P < 0.05) are in bold.
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
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expressers, and we observed 32% (35 cases) expressing
high MAP-tau compared with 68% (73 cases) showing
low expression in TAX 307S (Table 5). This result is con-
sistent with the MAP-tau expression distribution in the
Yale University cohort (22% high MAP-tau and 78% low
MAP-tau expression; P = 0.21 and P = 0.43, respectively).
In TAX 307S, as in the Yale cohort above, low MAP-
tau expression was significantly more frequent in ER-
negative cases (35.6%) compared with ER-positive cases
(28.9%; P = 0.005). MAP-tau expression was also asso-
ciated with prior adjuvant chemotherapy (anthracyclines
only) with low MAP-tau expression most frequently
observed in patients receiving adjuvant chemotherapy
(39.8%). MAP-tau expression did not correlate with
menopausal status, tumor size, tumor grade, nodal status,
PR status, response to therapy, treatment arm, or prior
adjuvant or metastatic endocrine therapy.
MAP-tau prognostic value in TAX 307S
Comparison analysis of TAC vs FAC treatment arms
alone (not stratified by MAP-tau) in TAX 307S showed
no difference in TTP (P = 0.312; Figure 4a) and con-
firmed original TAX 307 clinical trial results which
showed no differences in median TTP (P = 0.51) or OS
(P = 0.93), with a median TTP of 31 versus 29 weeks and
median OS of 21 versus 22 weeks for TAC versus FAC,
respectively. Improved median five-year DFS was
observed for patients in TAX 307 who received TAC ver-
sus FAC (69% v 52%; P = 0.04) and the inclusion of
MAP-tau expression in the Yale University Cohort
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Figure 2 Kaplan Meier survival analysis and MAP-tau expression in Yale University cohort. (a) Ten-year survival for high MAP-tau
expression versus low expression for all invasive breast carcinoma patients in the Yale University cohort (n = 651). Survival rate for patients
classified as high MAP-tau expressors (n = 94) was 68.3% compared with 52.9% for low expressors (n = 339; log-rank, P = 0.006). (b) Kaplan
Meier survival for MAP-tau expression stratified by eatrogen receptor (ER) status in the Yale University cohort. For ER-negative patients (inset),
high MAP-tau expression (n = 35) showed improved survival compared with low (n = 209) expression. (c) Ten-year survival for MAP-tau
expression stratified by human epidermal growth factor receptor (HER) 2 status in the Yale University cohort. Patients classified as high MAP-Tau
expressors showed improved survival compared with low expressors, regardless of HER2 status. For ER-negative patients stratified by HER2 status
(inset), ER-negative patients with high MAP-tau expression (n = 30) trended toward improved survival, regardless of HER2 status, compared with
low MAP-tau expressors (n = 56) (68.4% v 45.3%; log-rank, P = 0.068).
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Page 7 of 18Table 3 Univariate analysis of tumor and clinical risk factors for overall survival in the Yale University cohort
Yale University cohort
Variable No. of patients (%) (n = 651) HR 95% CI P*
Age at diagnosis 645 (99.1) 0.999 0.988-1.009 0.890
Unknown/missing 6 (0.9)
Menopausal status
Premenopausal 196 (30.1) 1.000 0.436
Postmenopausal 449 (69.0) 1.115 0.848-1.482
Unknown/missing 6 (0.9)
Tumor size (cm)
≤ 2 215 (33.0) 1.000 < 0.0001
2-5 283 (43.5) 1.682 1.254-2.258
≥ 5 101 (15.5) 2.911 2.074-4.086
Other 52 (8.0)
Nodal status
Negative for node metastasis 327 (50.2) 1.000 < 0.0001
Positive for node metastasis 320 (49.2) 2.286 1.795-2.910
Unknown/missing 4 (0.6)
Positive nodes 320 (49.2) 1.022 1.001-1.042 0.040
Total nodes 625 (96.0) 0.978 0.961-0.994 0.010
Unknown/missing 26 (4.0)
Nuclear grade
Small/uniform nuclei 113 (17.4) 1.000 0.0007
Intermediate nuclei 315 (48.4) 1.231 0.854-1.818
Large nuclei 170 (26.1) 1.594 1.192-2.123
Other 53 (8.1)
ER status
ER negative 289 (44.4) 1.000 0.0005
ER positive 326 (50.1) 0.766 0.598-0.981
Other 36 (5.5)
PR status
PR negative 294 (45.2) 1.000 < 0.0001
PR positive 302 (46.4) 0.675 0.524-0.871
Other 55 (8.4)
HER2 status
HER2 negative 495 (76.0) 1.000 0.153
HER2 positive 109 (16.7) 1.270 1.048-1.317
Other 47 (7.2)
MAP-tau expression
MAP-tau low expression 376 (57.8) 1.000 0.0042
MAP-tau high expression 104 (16.0) 0.691 0.489-0.974
Unknown/missing 171 (26.3)
* P is given for Cox univariate analysis, statistically significant P values (P < 0.05) are in bold, trending P values are in italics; CI, confidence interval; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
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Page 8 of 18Table 4 Cox proportional hazards multivariate model for overall survival in the Yale University cohort
Yale University cohort
Variable No. of patients (%) (n = 651) HR 95% CI P*
Age at diagnosis 645 (99.1) 1.004 0.981-1.026 0.718
Unknown 6 (0.9)
Menopausal status
Premenopausal 196 (30.1) 1.000 0.339
Postmenopausal 449 (69.0) 1.158 0.857-1.569
Other 6 (0.9)
Tumor size (cm)
≤ 2 215 (33.0) 1.000 < 0.0001
2-5 283 (43.5) 1.880 1.255-2.865
≥ 5 101 (15.5) 1.988 1.323-2.951
Unknown 52 (8.0)
Nodal status
Negative for node metastasis 327 (50.2) 1.000 < 0.0001
Positive for node metastasis 320 (49.2) 1.578 1.307-1.922
Unknown 4 (0.6)
Total nodes 625 (96.0) 0.976 0.956-0.996 0.022
Unknown 26 (4.0)
Nuclear grade
Small/uniform nuclei 113 (17.4) 1.000 0.421
Intermediate nuclei 315 (48.4) 1.015 0.624-1.725
Large nuclei 170 (26.1) 1.272 0.868-1.853
Unknown 53 (8.1)
ER status
ER negative 289 (44.4) 1.000 0.308
ER positive 326 (50.1) 0.903 0.740-1.097
Unknown 36 (5.5)
PR status
PR negative 294 (45.2) 1.000 0.433
PR positive 302 (46.4) 0.929 0.769-1.114
Unknown 55 (8.4)
HER2 status
HER2 negative 495 (76.0) 1.000 0.020
HER2 positive 109 (16.7) 1.292 1.041-1.586
Unknown 47 (7.2)
MAP-tau expression
MAP-tau low expression 376 (57.8) 1.000 0.018
MAP-tau high expression 104 (16.0) 0.765 0.598-0.957
Other 171 (26.3)
* P is given for Cox multivariate analysis, statistically significant P values (P < 0.05) are in bold, trending P values are in italics; CI, confidence interval; ER, estrogen
receptor; HR, hazard ratio; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.
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Page 9 of 18docetaxel resulted in higher overall response rates for
TAC versus FAC (55% vs 44%; P = 0.02) [16].
When TAX 307S (TAC plus FAC arms combined)
was stratified by MAP-tau expression, we observed
prognostic value for MAP-tau with improved median
time to PFS for high MAP-tau expressers (n = 35) com-
pared with low expressers (n = 73; 33.0 v 23.4 months)
and a mean TTP of 31.2 months (log-rank, P = 0.010;
Figure 4b), suggesting that this marker maintains prog-
nostic value in metastatic patients.
MAP-tau predictive value in TAX 307S
Stratification by both treatment arm and MAP-tau expres-
sion showed improved TTP for high MAP-tau expression,
regardless of treatment, which indicated prognostic but
not predictive value for MAP-tau (Figure 4c, log-rank, P =
0.006). In addition, no significant interaction between
MAP-tau expression and benefit from docetaxel (P =
0.843) was observed further confirming the finding of no
predictive value for MAP-tau in TAX 307S. High MAP-
tau expression was associated with improved PFS (HR:
0.538; 95% CI, 0.333 to 0.871; P = 0.011), whereas tumor
non-response (stable disease plus progressive disease) was
associated with worse PFS (HR: 2.213; 95% CI, 1.404 to
3.488; P = 0.0006; Table 6). Multivariate Cox proportional
hazards regression analysis showed only high MAP-tau
expression was associated with significantly better TTP.
For these patients, we observed a 69% reduction of risk of
progression (HR = 0.308; 95% CI, 0.130 to 0.728, P =
0.007; Table 7).
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Figure 3 MAP-tau expression and frequency distribution in TAX 307S whole tissue sections. (a) Whole section breast tumor tissue from
patient case 24 stained with hematoxylin and eosin showing dark pink staining of tumor cytoplasm compared with blue nuclei staining (red
arrows); remaining light pink or non-staining, mesh-like areas comprised of breast adipose tissue (black arrow). Original magnification × 4. (b)
Whole tissue slide of breast tumor tissue from panel a (case 24) stained with MAP-tau-Cy5 and analyzed using AQUA digital pathology
algorithms. A matrix captured 103 quadrants (41 quadrants displayed in panel b and was used to systematically capture each field of view (FOV),
creating 103 unique expression scores for case 24. Original magnification × 4. (c) Frequency distribution for MAP-tau quadrant scores from case
24 with mean and median AQUA scores of 1357 and 1369, respectively, and a score range of 610 to 1986. FOVs were used to generate a
frequency distribution for each case in the TAX 307S cohort (n = 140). The median AQUA score from each case was used in all cohort analyses.
(d) Distribution of MAP-tau expression in TAX307.
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Page 10 of 18Table 5 Correlation between MAP-tau expression and clinicopathologic variables in TAX 307S
MAP-tau expression
Variable Low (%) (AQUA score < 462) High (%) (AQUA score > 462) P*
Menopausal status
Premenopausal 15 (17.1) 9 (10.2) 0.487
Postmenopausal 45 (51.1) 19 (21.6)
Tumor size (cm)
≤ 2 13 (12.8) 11 (10.8) 0.137
2-5 40 (39.2) 16 (15.6)
≥ 5 15 (14.7) 7 (6.9)
Nodal status
Negative for node metastasis 23 (24.2) 10 (10.5) 0.922
Positive for node metastasis 41 (43.2) 21 (22.1)
Tumor grade 0.140
Well/moderately differentiated 19 (21.1) 12 (13.3)
Poorly/undifferentiated 45 (50.0) 14 (15.6)
ER status
ER negative 32 (35.6) 8 (8.9) 0.005
ER positive 26 (28.9) 24 (26.7)
PR status
PR negative 30 (34.5) 11 (12.6) 0.103
PR positive 26 (29.9) 20 (22.9)
Prior adjuvant chemotherapy
No therapy 30 (27.8) 25 (23.2) 0.002
Yes therapy 43 (39.8) 10 (9.3)
Prior adjuvant hormonal therapy
No therapy 47 (43.5) 24 (22.2) 0.666
Yes therapy 26 (24.1) 11 (10.2)
Prior metastatic hormonal therapy
No therapy 56 (51.9) 24 (22.2) 0.371
Yes therapy 17 (15.7) 11 (10.2)
Response to therapy
Complete response (CR) 6 (5.9) 2 (1.9) 0.518
Partial response (PR) 30 (29.7) 18 (17.8)
Stable disease (SD) 20 (19.8) 9 (8.9)
Progressive disease (PD) 13 (12.9) 3 (2.9)
Treatment
FAC
1 39 (36.1) 15 (13.9) 0.303
TAC
2 34 (31.5) 20 (18.5)
*P is given for chi-square analysis. Statistically significant P values (P < 0.05) are in bold.
1FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination
2TAC, docetaxel-doxorubicin-cyclophosphamide combination
ER, estrogen receptor; PR, progesterone receptor.
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Page 11 of 18MAP-tau is an ER-regulated gene with inducible
expression by both estrogen and tamoxifen, in vitro
[20]. ER positivity and/or tamoxifen therapy could act
by artificially elevating MAP-tau levels and obscuring
the relation between MAP-tau expression level and
response to taxane therapy. Thus we stratified this
cohort by adjuvant endocrine therapy, ER status, and
also TAC vs FAC treatment. Stratification by ER status
showed a trend, but not significant association between
MAP-tau expression and TTP (Figure 4d, log-rank, P =
0.0615). Next, we correlated MAP-tau expression levels
with response to docetaxel therapy. Response rates as a
function of MAP-tau expression did not differ when
split by ER status, adjuvant endocrine therapy, or taxane
treatment arm (TAC vs FAC; Table 8).
Discussion
Although previous literature shows conflicting results for
MAP-tau prognostic and predictive value, in this study of
two independent cohorts, we find MAP-tau expression has
prognostic value. In both a population-based retrospective
cohort, and a randomized clinical trial with taxane as the
only variable and uniformly treated metastatic patients,
high levels of MAP-tau, a microtubule stabilizing protein,
were associated with better outcomes. Increased microtu-
bule stability may be associated with less aggressive tumors.
However, the mechanistic reason for this observation is
unknown. Furthermore, there is no correlation with
nuclear grade in either cohort, suggesting that MAP-tau is
not related to the molecular parameters that drive the mor-
phological features contributing to nuclear grade.
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Figure 4 Progression free survival by treatment arm and MAP-tau status in TAX 307S whole tissue sections. (a) Survival analysis for TAC
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clinical trial results (n = 484). (B) Median progression free survival for patients classified as high MAP-tau expressors (n = 35) was 33.0 v 23.4
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Page 12 of 18Table 6 Univariate analysis of tumor and clinical risk factors for progression-free survival in TAX 307S
TAX 307S cohort
Variable No. of patients (n = 140) HR 95% CI P*
Age 108 (77.1) 0.977 0.955-1.00 0.060
Other 10 (7.1)
Unknown 22 (15.7)
Menopausal status
Premenopausal 29 (20.7) 1.000 0.083
Postmenopausal 79 (56.4) 0.627 0.375-1.046
Other 10 (7.1)
Unknown 22 (15.7)
Tumor size (cm)
≤ 2 24(17.1) 1.000 0.580
2-5 56 (40.0) 0.728 0.567-1.136
≥ 5 22 (15.8) 1.134 0.641-2.142
Other 15 (10.7)
Unknown 23 (16.4)
Nodal status
Negative for node metastasis 33 (23.6) 1.000 0.119
Positive for node metastasis 62 (44.3) 0.993 0.595-1.249
Other 23 (16.4)
Unknown 22 (15.7)
Tumor grade
Well/moderately differentiated 31 (22.1) 1.000 0.163
Poorly/undifferentiated 59 (42.1) 1.412 0.758-1.904
Other 28 (20.1)
Unknown 22 (15.7)
ER status
ER negative 40 (28.6) 1.000 0.236
ER positive 50 (35.7) 0.750 0.465-1.208
Other 28 (20.0)
Unknown 22 (15.7)
PR status
PR negative 41 (29.3) 1.000 0.847
PR positive 46 (32.9) 0.954 0.592-1.538
Other 31 (22.1)
Unknown 22 (15.7)
Prior adjuvant chemotherapy
No therapy 55 (39.3) 1.000 0.983
Yes therapy 53 (37.9) 1.005 0.656-1.538
Other 10 (7.1)
Unknown 22 (15.7)
Prior adjuvant hormonal therapy
No therapy 71 (50.7) 1.000 0.512
Yes therapy 37 (26.4) 0.859 0.549-1.349
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Page 13 of 18Table 6 Univariate analysis of tumor and clinical risk factors for progression-free survival in TAX 307S (Continued)
Other 10 (7.1)
Unknown 22 (15.7)
Prior metastatic hormonal therapy
No therapy 80 (57.1) 1.000 0.176
Yes therapy 28 (20.0) 0.711 0.434-1.165
Other 10 (7.1)
Unknown 22 (15.7)
Response to therapy
Responder 56 (40.0) 1.000 1.404-3.488 0.0006
Non-responder 45 (32.2) 2.213
Other 17 (12.1)
Unknown 22 (15.7)
Treatment
FAC
1 54 (38.6) 1.000 0.315
TAC
2 54 (38.6) 1.256 0.805-1.960
Other 10 (7.1)
Unknown 22 (15.7)
MAP-tau expression
MAP-tau low expression 73 (52.1) 1.000 0.011
MAP-tau high expression 35 (25.0) 0.538 0.333-0.871
Other 10 (7.1)
Unknown 22 (15.7)
* P is given for Cox multivariate analysis, statistically significant P values (P < 0.05) are in bold, trending P values are in italics;
1FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination
2TAC, docetaxel-doxorubicin- cyclophosphamide combination
CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor.
Table 7 Cox proportional hazards multivariate model in TAX 307S
TAX 307S cohort
Variable No. of patients (%) (n = 140) HR 95% CI P*
Age 108 (77.1) 0.972 0.934-1.011 0.153
Other 10 (7.1)
Unknown 22 (15.7)
Tumor size (cm)
≤ 2 24(17.1) 1.000 0.224
2-5 56 (40.0) 1.116 0.280-4.444
≥ 5 22 (15.8) 1.326 0.433-4.065
Other 15 (10.7)
Unknown 23 (16.4)
Nodal status
Negative for node metastasis 33 (23.6) 1.000 0.207
Positive for node metastasis 62 (44.3) 3.364 0.792-14.297
Other 23 (16.4)
Unknown 22 (15.7)
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Page 14 of 18Table 7 Cox proportional hazards multivariate model in TAX 307S (Continued)
Tumor grade
Well/moderately differentiated 31 (22.1) 1.000 0.773
Poorly/undifferentiated 59 (42.1) 0.897 0.430-1.875
Other 28 (20.1)
Unknown 22 (15.7)
ER status
ER negative 40 (28.6) 1.000 0.524
ER positive 50 (35.7) 1.353 0.533-3.424
Other 28 (20.0)
Unknown 22 (15.7)
PR status
PR negative 41 (29.3) 1.000 0.751
PR positive 46 (32.9) 1.154 0.475-2.801
Other 31 (22.1)
Unknown 22 (15.7)
Prior adjuvant chemotherapy
No therapy 55 (39.3) 1.000 0.604
Yes therapy 53 (37.9) 0.835 0.422-1.650
Other 10 (7.1)
Unknown 22 (15.7)
Prior adjuvant hormonal therapy
No therapy 71 (50.7) 1.000 0.810
Yes therapy 37 (26.4) 0.909 0.417-1.980
Other 10 (7.1)
Unknown 22 (15.7)
Prior metastatic hormonal therapy
No therapy 80 (57.1) 1.000 0.456
Yes therapy 28 (20.0) 0.714 0.295-1.730
Other 10 (7.1)
Unknown 22 (15.7)
Treatment
FAC
1 54 (38.6) 1.000 0.264
TAC
2 54 (38.6) 1.517 0.729-3.154
Other 10 (7.1)
Unknown 22 (15.7)
MAP-tau expression
MAP-tau low expression 73 (52.1) 1.000 0.007
MAP-tau high expression 35 (25.0) 0.308 0.130-0.728
Other 10 (7.1)
Unknown 22 (15.7)
*P is given for Cox multivariate analysis, statistically significant P values (P < 0.05) are in boldface, trending values are in italics; CI, confidence interval; ER,
estrogen receptor; HR, hazard ratio; PR, progesterone receptor.
1FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination.
2TAC, docetaxel-doxorubicin-cyclophosphamide combination.
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Page 15 of 18Table 8 MAP-tau expression levels and response to docetaxel in TAX 307S
TAX 307S Patient groups N Objective response
4
(CR + PR) (%)
Stable disease
5
(SD) (%)
Progressive disease
(PD) (%)
Total Missing P*
ER positive 0.174
High MAP-tau 15 (33.3) 5 (11.1) 1 (2.2) 21 (46.7)
Low MAP-tau 10 (22.2) 10 (22.2) 4 (8.9) 24 (53.3)
Total 50 25 (55.8) 15 (33.3) 5 (11.1) 45 (100.0) 5
ER negative 0.721
High MAP-tau 4 (10.5) 4 (10.5) 0 (0.0) 8 (21.0)
Low MAP-tau 15 (39.5) 13 (34.2) 2 (5.3) 30 (78.9
Total 40 19 (49.9) 17 (44.8) 2 (5.3) 38 (100.0) 2
FAC
1 and TAC
2 0.518
High MAP-tau 20 (19.7) 9 (8.9) 3 (2.9) 32 (31.7)
Low MAP-tau 36 (35.6 20 (19.8) 13 (12.9) 69 (68.3)
Total 108 56 (55.4) 29 (28.7) 16 (15.8) 101
(100.0)
7
TAC
2 only 0.250
High MAP-tau 11 (22.4) 7 (14.3) 1 (2.0) 19 (38.8)
Low MAP-tau 17 (34.7) 7 (14.3) 6 (12.2) 30 (61.2)
Total 54 28 (57.1) 14 (28.6) 7 (14.3) 49 (100.0) 5
TAC
2 and ER positive 0.520
High MAP-tau 9 (45.0) 4 (20.0) 1 (5.0) 14 (70.0)
Low MAP-tau 2 (10.0) 3 (15.0) 1 (5.0) 6 (30.0)
Total 20 11 (55.0) 7 (35.0) 2 (10.0) 20 (100.0) 0
TAC
2/ER negative/Adj Hormonal
-negative
3
0.222
High MAP-tau 2 (10.0) 2 (10.0) 0 (0.0) 4 (20.0)
Low MAP-tau 8 (40.0) 3 (15.0) 5 (25.0) 16 (80.0)
Total 20 10 (50.0) 5 (25.0) 5 (25.0) 20 (100.0) 0
FAC
1 only 0.514
High MAP-tau 9 (17.3) 2 (3.9) 2 (3.9) 13 (25.0)
Low MAP-tau 19 (36.6) 13 (25.0) 7 (13.5) 39 (75.0)
Total 54 28 (53.9) 15 (28.9) 9 (17.3) 52 (100.0) 2
FAC
1 and ER positive 0.105
High MAP-tau 6 (24.0) 1 (4.0) 0 (0.0) 7 (28.0)
Low MAP-tau 8 (32.0) 7 (28.0) 3 (12.0) 18 (72.0)
Total 28 14 (56.0) 8 (32.0) 3 (12.0) 25 (100.0) 3
FAC
1 and ER negative 0.919
High MAP-tau 2 (11.1) 1 (5.6) 1 (5.6) 4 (22.2)
Low MAP-tau 7 (38.9) 5 (27.8) 2 (11.1) 14 (77.8)
Total 18 9 (50.0) 6 (33.3) 3 (16.7) 18 (100.0) 0
*P is given for chi-square analysis. Statistically significant P values (P < 0.05) are in bold.
1FAC, 5-fluorouracil-doxorubicin-cyclophosphamide combination
2TAC, docetaxel-doxorubicin-cyclophosphamide combination
3Adjuvant hormonal therapy-negative patients only
4Objective response, complete response (CR) + partial response (PR)
5Stable disease defined as minimum of 6 weeks (2 cycles) ER, estrogen receptor; PR, progesterone receptor
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predictive value, we find no evidence for use of this
marker as a companion diagnostic test to predict
response to taxane therapy. A previous study showed
mechanistic evidence for competitive binding between
taxanes and MAP-tau [7]. That finding generated the
hypothesis that expression levels of MAP-tau would be
predictive of the effect of taxanes. However, this study is
now the second cohort to fail to show an association
between MAP-tau expression levels and response to tax-
ane therapy in the metastatic setting. Although both stu-
dies [15] are relatively small, the lack of association in
either case raises question regarding the value of mea-
suring MAP-tau in large taxane trials.
Previous studies have shown interactions between tax-
ane therapy and standard breast cancer biomarkers such
as ER and HER2 [21-23]. There is a good mechanistic
explanation for this finding in the case of ER because
MAP-tau is induced by activation of ER by either estro-
gen or other selective-estrogen receptor modulators
(tamoxifen) [20]. When the Yale cohort was stratified by
ER status, MAP-tau expression was prognostic only in
ER-negative patients. Multivariate analysis indicated that
high MAP-tau remained a significant predictor of
improved survival for ER-negative patients even after
adjusting for tumor size and nodal status. As the ER-
negative tumors are presumed to have lost ER function,
the presence of MAP-tau may be regulated by other
mechanisms. It is also possible that some of the ER-nega-
tive cases are really low positives or false negatives. In
another study of this cohort, approximately 10% of the
E R - n e g a t i v ec a s e sw e r es h o w nt ob eE Rp o s i t i v e[ 2 4 ] .
Furthermore, in an analysis not shown, we find a correla-
tion between ER expression and MAP-tau expression
raising the possibility that high MAP-tau is a surrogate
for ER. However, the relatively small numbers of patients
in these subgroups make it difficult to drawn convincing
conclusions. Previous efforts to examine MAP-tau pro-
tein expression as a function of ER status have shown no
prognostic value [12]. Other studies examining MAP-tau
mRNA have also observed no prognostic value when
stratified by ER status [11]. However, Andre and collea-
gues examined mRNA expression in a treated ER-positive
cohort and showed low MAP-tau was associated with
worse outcome [9,12]. The lack of agreement between
these studies may be due to disparities between RNA and
protein expression.
Conclusions
In this study of two independent cohorts, MAP-tau pro-
tein expression is shown to be prognostic but has no
predictive value for response to docetaxel. The data
from this and other studies is based largely on small,
single-institution, retrospective studies. However, the
lack of a promising result makes it difficult to justify
measurement of MAP-tau in the clinical setting or even
one of the cooperative group trials for taxane therapy.
This is disappointing because a companion diagnostic
test for taxane class drugs would be valuable. Future
efforts evaluating other MAPs are needed and may be
more fruitful.
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